KRAS and prostate carcinoma: This includes the CUB and Sushi multiple domains protein 3 (CSMD3) mutations in ovarian cancer,[9] the mucin 4 mutations in colon cancer,[10] ryanodine receptor 2 in breast cancer,[11] tumor protein P53 (TP53) in prostate cancer and hepatocellular carcinoma,[12] etc. Furthermore, titin (TTN),[13] TP53, KRAS proto-oncogene and GTPase (KRAS),[14] epidermal growth factor receptor,[15] Kelch-like ECH-associated protein (KEAP1)[16] have significant relevance with the carcinogenesis and prognosis in LUAD patients.